April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
In vitro Diffusion and Permeability of a Novel Intraocular Drug Delivery Implant
Author Affiliations & Notes
  • R. M. Burr
    Bioengineering,
    University of Utah, Salt Lake City, Utah
  • S. A. Molokhia
    Ophthalmology,
    University of Utah, Salt Lake City, Utah
  • C. J. Bishop
    Bioengineering,
    University of Utah, Salt Lake City, Utah
  • H. J. Sant
    Mechanical Engineering,
    University of Utah, Salt Lake City, Utah
  • J. M. Simonis
    Ophthalmology,
    University of Utah, Salt Lake City, Utah
  • B. K. Gale
    Mechanical Engineering,
    University of Utah, Salt Lake City, Utah
  • B. K. Ambati
    Ophthalmology, John Moran Eye Center, Salt Lake City, Utah
  • Footnotes
    Commercial Relationships  R.M. Burr, None; S.A. Molokhia, None; C.J. Bishop, None; H.J. Sant, None; J.M. Simonis, None; B.K. Gale, WO 2009140246, P; B.K. Ambati, WO 2009140246, P.
  • Footnotes
    Support  Technology Commercialization Project Grant from the University of Utah
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5299. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. M. Burr, S. A. Molokhia, C. J. Bishop, H. J. Sant, J. M. Simonis, B. K. Gale, B. K. Ambati; In vitro Diffusion and Permeability of a Novel Intraocular Drug Delivery Implant. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5299.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To design a novel ring shaped device intended for implantation in the lens capsular bag at the time of cataract surgery.

Methods: : To control the release of Avastin® we have investigated 3 commercially available hydrophilic and biocompatible membranes: Polyethersulfone (PES), Polycarbonate (PC), and Polyvinylidene Fluoride. The membrane is attached to a 1 - 4 mm2 hole that has been previously cut in a controlled drug delivery ring (CDR). An rhVEGF ELISA with known concentrations for calibration was used to assay samples collected. Side by side diffusion chambers of 2 ml each (donor and receiver) were used to identify the permeability coefficients of our Avastin® formulation for each membrane. 1 ml samples were taken from the receiver and replaced with an equal volume of fresh PVA every 2 to 6 hours for a maximum of 24 hours. We also conducted drug release studies using the PES and PC membranes to determine diffusion coefficients for later translation into a suitable in vivo Avastin® formulation. Samples were taken and replaced with an equal volume of fresh BSS daily for the first week and 1 - 2 times per week thereafter until no Avastin® was detected.

Results: : The CDR will provide long-term sustained release of drug from a 100 µl reservoir. One candidate drug that we are investigating is Avastin® which is currently administered via intravitreal (IV) injections at 1.25 mg/month. We have formulated Avastin® with a polyvinyl alcohol (PVA) polymer to increase Avastin® stability and slow the release rate from the CDR. CDRs were filled with 50 - 100 µl of 12.5 and 25 mg/ml Avastin® solutions and placed in 4 ml of balanced salt solution. We found continuous elution for >2 months and therefore the CDR is a plausible alternative to monthly IV injections.

Conclusions: : In vitro diffusion studies confirm long-term release of Avastin® from the CDR.

Keywords: drug toxicity/drug effects • anterior chamber 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×